Trials / Completed
CompletedNCT04771780
Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
A Phase 3, Long-term, Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 213 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK7791 | oral administration |
Timeline
- Start date
- 2021-03-15
- Primary completion
- 2022-06-27
- Completion
- 2022-06-27
- First posted
- 2021-02-25
- Last updated
- 2023-08-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04771780. Inclusion in this directory is not an endorsement.